- Celltrion , prior to the global pharmaceutical FDA innovative therapeutics ' sol Rare ' bio-Miller accelerate development -??Global?3?1 trillion?3?100 000 000 000 to preempt the market?2022?will completed by early commercialization to the clinical years -??First mover to acquire a bio-Miller experienced?R & D?focused portfolio of capabilities extend Spurs   [2019?years?7?Mon?15?days?]?Celltrion allergic asthma and chronic urticaria cure the?"?sol Rare?(Xolair -?Ingredient Name?:?O'Malley jumap?) '?biosimilars in the?' CT-P39 '?clinical?first?phase?^[1]?in earnest Comes out?.   Celltrion for the safety and pharmacokinetic evaluation?first?to start a Phase I clinical trial The?2020?first half-year global clinical?three?plan to plunge on the?2022?up to year?three?plans all out for early commercialization as a target for clinical complete?.   Sol Rare Genentech?(Genentech)?and Novartis?(Novatis)?to the antibody biopharmaceutical development?2018?end of?IQVIA?global revenues in aggregate based on?3one trillion?3000?a blockbuster product recorded one hundred million won?.   Celltrion began?the development?of the?CT-P39?, a biosimilar, based on the fact that the?expiration of a material patent in the US, which accounts?for?70%?of Zolare's global sales,?will?expire?in?December?2018?.?In particular?,?selteu?Leone Ram Island?,?teuruk Island and to proactively than the large global pharmaceutical companies successfully developed and allowed jyuma experience successful commercialization of?CT-P39?started to develop?.   CT-P39?is a biosimilar of current clinical progress of Celltrion?CT-P17 (?Humira biosimilars?), CT-P16 (?Avastin biosimilars?)?followed by?6?is an antibody biosimilar to rush into a clinical second?. Ram Island of Celltrion?,?teuruk Shima?,?huh jyuma is already surpass the competition in the global market, and becoming gain market share and half?EMA?expectations Ram Island authorizing?SC?current and?three?phase III clinical progress,?CT-P17 (?Humira biosimilars?) , CT-P16 (?Avastin Biosimilars?)?, and?CT-P39?, Celltrion has secured a more diversified portfolio than its global competitors?.?Celltrion?plans to move forward more proactively to expand its portfolio by focusing on?R & Dcapabilities?acquired through the development of biosimilar first mover, led by Ramshima?.   Celltrion official?"?sol Rare last?FDA?was designated as innovative therapeutics from?,?original drug developer also based on the innovation of products biopharmaceutical products that committed the indication expansion?,"?said?"?Celltrion more patients to earlier time within reasonable cost so that the treatment can be a rare bio-sol will do my best to obtain a first-mover status Miller?, "?he said?.   Meanwhile, the official said,?"?Celltrion and diseases in addition to the field of autoimmune diseases and cancer fields of existing products continue to progress the global pharmaceutical market research and studies to expand our portfolio of antibody drugs?,"?he added